Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two Stage Trial of lenalidomide (Revlimid) : a Phase II Study of lenalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lenalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.

Trial Profile

A Two Stage Trial of lenalidomide (Revlimid) : a Phase II Study of lenalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of lenalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Carboplatin; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 02 Jun 2015 Lenalidomide + carboplatin + doxorubicin-liposomal was not feasible at the dose and schedules evaluated, mainly due to cumulative haematologic toxicity, according to results reported at ASCO 2015.
    • 02 Jun 2015 Interim results in 22 patients enrolled up to Jan 2014 presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO 2015).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top